# NCT04113616 (NCT04113616)

> An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04113616
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Kartos Therapeutics, Inc.
- Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
- Interventions: KRT-232; Cytarabine; Decitabine
- Enrollment: 70
- Primary outcome: Part A: To determine KRT-232 recommended phase 2 dose (RP2D)
- Primary outcome: Part B: To determine the RP2D of KRT-232

## Indexed commentary on NCT04113616 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04113616